Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRL_RI versus MabThera in previously untreated low-tumor-burden follicular lymphoma
2018-004223-36Phase 3Completed
- Sponsor
- Dr. Reddy's Laboratories
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoint: Best overall response rate. Started May 2019; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2018-004223-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004223-36.